|Bid||0.2975 x 4000|
|Ask||0.2916 x 4000|
|Day's Range||0.2930 - 0.3080|
|52 Week Range||0.2600 - 0.9600|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 15, 2022 - Feb 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.33|
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced results for its fiscal third quarter ended March 31, 2022.
PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?